Ionis Pharmaceuticals (IONS) Reports In-Line Q3 EPS

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($1.03), in-line with the analyst estimate of ($1.03). Revenue for the quarter came in at $144 million versus the consensus estimate of $132.91 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Ionis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim
• Live Oak Bancshares, Inc. (LOB) Tops Q2 EPS by 6c
• United Rentals (URI) Tops Q2 EPS by $1.23